FDA Adds Bladder Cancer Warnings to Takeda's Actos
The U.S. FDA has concluded that use of Takeda ' s Actos (pioglitazone), a type 2 diabetes medicine, may be linked to an increased risk of bladder cancer and has approved label updates. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - December 14, 2016 Category: Pharmaceuticals Source Type: news
FDA Affirms Pioglitazone May Be Tied to Higher Bladder Cancer Risk (FREE)
By Kristin J. Kelley
Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM
The type 2 diabetes drug pioglitazone may pose an increased risk for bladder cancer, the FDA … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 13, 2016 Category: Primary Care Source Type: news
FDA Still Sees Bladder Cancer Risk With Pioglitazone FDA Still Sees Bladder Cancer Risk With Pioglitazone
The agency reviewed new and conflicting research on the possible cancer risk of the diabetes drug and came down again on the side of risk.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 13, 2016 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news
FDA Affirms Bladder Cancer Warning for Pioglitazone
(MedPage Today) -- Agency unpersuaded by manufacturer-sponsored study asserting no risk (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - December 12, 2016 Category: Endocrinology Source Type: news
FDA Drug Safety Communication: Updated FDA review concludes that use of type 2 diabetes medicine pioglitazone may be linked to an increased risk of bladder cancer
[12-12-2016] As a result of an updated review, the U.S. Food and Drug Administration (FDA) has concluded that use of the type 2 diabetes medicine pioglitazone (Actos, Actoplus Met, Actoplus Met XR, Duetact, Oseni) may be linked to an increased risk of bladder cancer. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 12, 2016 Category: Drugs & Pharmacology Source Type: news
Some drugs, banned in other countries, allowed in India: Government
Minister of State for Health Faggan Singh Kulaste in a written reply said that the drugs which have been allowed are nimesulide, analgin and pioglitazone. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 25, 2016 Category: Pharmaceuticals Source Type: news
Expensive New Diabetes Drugs Add Nothing But Cost And Complications
This is the fourth in an ongoing series of blogs exposing the rampant misuse of the medications so aggressively promoted by greedy drug companies.
I am very lucky in having the perfect partner in this truth-vs-power effort to contradict Pharma propaganda with evidence based fact.
Dick Bijl is President of the International Society of Drug Bulletins (ISDB), an impressive association of 53 national drug bulletins from all around the world, each of which publishes the best available data on the pluses and minuses of different medications.
Drug bulletins help patients and doctors see through the misleading misinformation ge...
Source: Science - The Huffington Post - November 17, 2016 Category: Science Source Type: news
Actos (pioglitazone)
Title: Actos (pioglitazone)Category: MedicationsCreated: 11/28/1999 12:00:00 AMLast Editorial Review: 9/20/2016 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - September 20, 2016 Category: Endocrinology Source Type: news
3 Drugs with the Most Severe Side Effects
Image Source
Drugs have been known to have some sort of side effects on patients. Most of them are not often discussed in the health tabloids. While other drugs have side effects that are very nominal when compared to the benefits the patient derives from their usage, others have side effects that can impact the lives of their users forever.
The most common side effects people experience from drug usage are gastrointestinal related issues which include constipation, nausea, and vomiting. Some other drugs can leave you feeling tired and dizzy for a short period of time. Combining these drugs with simple aspirin will usuall...
Source: Healthy Living - The Huffington Post - August 19, 2016 Category: Consumer Health News Source Type: news
Pioglitazone Diabetes Prevention Data Now Published Pioglitazone Diabetes Prevention Data Now Published
Reductions in both cardiovascular events and progression to diabetes suggest that a reexamination of pioglitazone ' s risk/benefit profile may be in order.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - August 12, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Pioglitazone Improves Fatty Liver in Prediabetes, Diabetes Pioglitazone Improves Fatty Liver in Prediabetes, Diabetes
Results of a single-center randomized trial suggest the drug may halt NASH progression and alter the natural history of the disease. Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - July 5, 2016 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Pioglitazone effective in diabetes patients with NASH
Pioglitazone may halt the progression of nonalcoholic steatohepatitis in patients with prediabetes or Type 2 diabetes, a randomised trial shows. (Source: MedWire News)
Source: MedWire News - June 27, 2016 Category: Consumer Health News Tags: Diabetes Source Type: news
Long-Term Pioglitazone Use Effective in Patients with NASH and Prediabetes or Diabetes (FREE)
By Atif Zaman, MD, MPH
Dr. Zaman is an associate editor with NEJM Journal Watch Gastroenterology, from which this story was adapted. Full coverage is available to subscribers at the link below.Pioglitazone is associated with improved disease activity in patients with nonalcoholic steatohepatitis (NASH) plus prediabetes or … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 20, 2016 Category: Primary Care Source Type: news
Pioglitazone safe and effective for steatohepatitis in T2DM
Long-term pioglitazone is not only safe for patients with nonalcoholic steatohepatitis (NASH) and prediabetes or type 2 diabetes but is associated with significant improvements in fatty liver disease... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - June 20, 2016 Category: Endocrinology Source Type: news
Pioglitazone Slows Progression to Type 2 Diabetes: More IRIS DataPioglitazone Slows Progression to Type 2 Diabetes: More IRIS Data
New and previously reported data from the IRIS trial prompt discussion of reevaluating the role of now-generic pioglitazone in the treatment and prevention of diabetes and stroke. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 17, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
